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Defining MoRAL After Liver Transplantation
Pierre A. Clavien, MD, PhD, Philipp Dutkowski, MD, and Keith D. Lillemoe, MDy
R ecently, a new score was proposed in this Journal
1 for identifying liver transplant HCC candidates
with low risk of recurrence after transplantation, despite classified beyond the widely accepted
Milan criteria. This scorewas nicknamed ‘‘MoRAL’’1 to stand for model for tumor recurrence of after
living donor liver transplantation (MoRAL).1 This scoring system combined serum a fetoprotein
(AFP) levels with another marker ‘‘prothrombin induced by vitamin K absence II (PIVKA-II)’’
enabling to identify significant longer recurrence-free survival in a large series of living donor
liver transplants with a c-statistic of 0.88 at a cut-off of 314.8. The MoRAL score formula
¼ 11 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPIVKAp þ 2x ﬃﬃﬃﬃﬃﬃﬃﬃﬃAFPp  appears rather simple, but with a need for further validation,
particularly in Western cohorts.2
The term MoRAL score has been introduced some years ago by the Columbia group3; at that
time standing for Model of Recurrence After Liver transplantation. This original MoRAL score was,
however, based on a different formula including AFP and neutrophil-to-lymphocyte ratio (NLR),
instead of PIVKA-II. The formula was designed to stratify the risk of tumor recurrence after liver
transplantation in patients with HCC.
In the current issue of the Journal, the same group now shows, mainly using cadaveric liver
grafts, high accuracy of their original formula in predicting tumor recurrence after transplantation by
combining AFP > 200, NLR 5, and tumor size 3 cm.4 Adding other parameters available after
surgery, such as vascular invasion and type of tumor histology achieved an impressive c-statistics of
0.91. The challenge, however, remains to define clinical thresholds when to say ,,no‘‘, i.e. denying
transplantation because of too high risk for tumor recurrence.
Both studies show that those patients with high MoRAL scores (cutoff 3151 or 104) do poorly
despite classified within Milan criteria (Table 1). In contrast, cases with low MoRAL scores showed
excellent outcome, even though being far outside ofMilan criteria (Table 1). Both studies, yet, clearly
suffer from too small caseload and too many patients with advanced tumor stages. To get wide
acceptance, both MoRAL scoring systems should therefore be validated in different populations, and
their predictive value convincingly compared.
Another aspect is the easiness of pre-transplant determination of scores. For
example, while calculation of NLR is readily available at most centers, PIVKA analysis is
less popular in Western countries. On the other hand, in a recent systematic review,
pretransplant PIVKA levels [or also named des-gamma-carboxy prothrombin (DCP)], besides
AFP, and allelic imbalance in microsatellites in DNA of tumor tissue were related to
tumor recurrence.5 This finding points towards the importance of further investigating useful
combinations of promising prognostic biomarkers to predict worse outcome in an era of extreme
scarce liver grafts.
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TABLE 1.
Initial MoRAL
score4
5 y recurrence
free survival
LDLT MoRAL
score1
5 y recurrence
free survival
Within Milan MoRAL 104 90% MoRAL 314.81 85%
MoRAL > 104 45% MoRAL > 314.81 50%
Outside Milan MoRAL 104 80% MoRAL 314.81 70%
MoRAL > 104 40% MoRAL > 314.81 18%
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